Clinical

Dataset Information

0

Phase I Clinical trial of personalized peptide vaccine in combination with humanized anti-IL6 receptor monoclonal antibody for refractory colorectal cancer patients


ABSTRACT: Interventions: Anti-IL6 receptor antibody [Actemra (tocilizumab), Chugai Pharmaceutical Co; 0.5mg/kg (n=6), 2mg/kg (n=6), or 8mg/kg (n=6)] is intravenously administrated. After three days, a maximum of 4 peptides (3 mg/each peptide), which are selected based on the results of HLA typing and peptide-specific IgG titers, are subcutaneously administrated with incomplete Freund’s adjuvant (Montanide ISA51, Seppic)once a week for consecutive 6 weeks. During the treatment, safety is evaluated.The dose of anti-IL6 receptor antibody is escalated, if the safty is confirmed in 6 independent patients at the same dose. Primary outcome(s): Safety (adverse events) of personalized peptide vaccine in combination with anti-IL6 receptor antibody. Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer Patients Refractory To Conventional Treatments

PROVIDER: 2622910 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2024-10-10 | PXD047749 | Pride
2018-02-22 | GSE104614 | GEO
2012-01-06 | E-GEOD-32316 | biostudies-arrayexpress
2018-07-17 | GSE117140 | GEO
2018-07-17 | GSE117141 | GEO
2015-10-25 | E-MTAB-3606 | biostudies-arrayexpress
2022-09-19 | GSE213482 | GEO
2023-03-31 | PXD040754 | Pride
2024-05-21 | PXD045817 | Pride
2014-05-30 | E-GEOD-53835 | biostudies-arrayexpress